- Revenue: $95.3B, +18% YoY
- Earnings per diluted share: $6.95, +57% YoY
- Adjusted Earnings per diluted share: $8.03, +4% YoY
CEO Brian Tyler: "McKesson reported strong third quarter operational results with broad-based Revenue growth of 18% and Adjusted Operating Profit growth of 16%. Our performance reflects the strength and momentum across the enterprise."
🌱Revenue & Growth
- U.S. Pharmaceutical: $87.1B, +19% YoY
- Prescription Technology Solutions: $1.4B, +14% YoY
- Medical-Surgical Solutions: $2.9B, -3% YoY
- International: $3.9B, +6% YoY
💰Profits & Financials
- Operating Profit: $1.29B, +91% YoY
- Adjusted Operating Profit: $1.46B, +16% YoY
- Free Cash Flow: -$2.2B vs -$251M in prior year
- Returned $3.1B to shareholders through share repurchases ($2.8B) and dividends ($254M)
📌Business Highlights
- Signed agreement to acquire 80% controlling interest in PRISM Vision Holdings
- Closed sale of Canada-based Rexall and Well .ca retail businesses
- Elected two new directors: Lynne Doughtie and Dr. Julie Gerberding
🔮Future Outlook
- Raised and narrowed FY2025 Adjusted EPS guidance to $32.55-$32.95 (previously $32.40-$33.00)
- Projecting 19-20% Adjusted EPS growth compared to prior year
- Will participate in TD Cowen 45th Annual Healthcare Conference on March 4, 2025